Genscript Biotech Stock Performance
| GNNSF Stock | USD 1.84 0.00 0.00% |
The company retains a Market Volatility (i.e., Beta) of 0.19, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Genscript Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Genscript Biotech is expected to be smaller as well. At this point, Genscript Biotech has a negative expected return of -0.15%. Please make sure to check out Genscript Biotech's variance, skewness, as well as the relationship between the Skewness and day typical price , to decide if Genscript Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Genscript Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
| Begin Period Cash Flow | 629.1 M | |
| Total Cashflows From Investing Activities | -212.5 M |
Genscript |
Genscript Biotech Relative Risk vs. Return Landscape
If you would invest 210.00 in Genscript Biotech on November 9, 2025 and sell it today you would lose (26.00) from holding Genscript Biotech or give up 12.38% of portfolio value over 90 days. Genscript Biotech is currently producing negative expected returns and takes up 3.4333% volatility of returns over 90 trading days. Put another way, 30% of traded pink sheets are less volatile than Genscript, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Genscript Biotech Target Price Odds to finish over Current Price
The tendency of Genscript Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.84 | 90 days | 1.84 | about 82.83 |
Based on a normal probability distribution, the odds of Genscript Biotech to move above the current price in 90 days from now is about 82.83 (This Genscript Biotech probability density function shows the probability of Genscript Pink Sheet to fall within a particular range of prices over 90 days) .
Genscript Biotech Price Density |
| Price |
Predictive Modules for Genscript Biotech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Genscript Biotech. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Genscript Biotech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Genscript Biotech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Genscript Biotech is not an exception. The market had few large corrections towards the Genscript Biotech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Genscript Biotech, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Genscript Biotech within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.17 | |
β | Beta against Dow Jones | 0.19 | |
σ | Overall volatility | 0.19 | |
Ir | Information ratio | -0.07 |
Genscript Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Genscript Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Genscript Biotech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Genscript Biotech generated a negative expected return over the last 90 days | |
| Genscript Biotech may become a speculative penny stock | |
| Genscript Biotech has high historical volatility and very poor performance | |
| The company reported the revenue of 510.6 M. Net Loss for the year was (347.87 M) with profit before overhead, payroll, taxes, and interest of 303.48 M. | |
| Genscript Biotech has accumulated about 1.26 B in cash with (136.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Roughly 38.0% of the company shares are held by company insiders |
Genscript Biotech Fundamentals Growth
Genscript Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Genscript Biotech, and Genscript Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genscript Pink Sheet performance.
| Return On Equity | -0.56 | |||
| Return On Asset | -0.12 | |||
| Profit Margin | (0.66) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | 5.11 B | |||
| Shares Outstanding | 2.12 B | |||
| Price To Earning | 200.00 X | |||
| Price To Book | 6.65 X | |||
| Price To Sales | 10.82 X | |||
| Revenue | 510.6 M | |||
| EBITDA | (494 M) | |||
| Cash And Equivalents | 1.26 B | |||
| Cash Per Share | 0.60 X | |||
| Total Debt | 121.07 M | |||
| Debt To Equity | 0.56 % | |||
| Book Value Per Share | 0.36 X | |||
| Cash Flow From Operations | (136.79 M) | |||
| Earnings Per Share | (0.17) X | |||
| Total Asset | 2.23 B | |||
About Genscript Biotech Performance
By analyzing Genscript Biotech's fundamental ratios, stakeholders can gain valuable insights into Genscript Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Genscript Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Genscript Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the Peoples Republic of China, Japan, the other Asia Pacific regions, and internationally. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the Peoples Republic of China. Genscript Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5573 people.Things to note about Genscript Biotech performance evaluation
Checking the ongoing alerts about Genscript Biotech for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Genscript Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Genscript Biotech generated a negative expected return over the last 90 days | |
| Genscript Biotech may become a speculative penny stock | |
| Genscript Biotech has high historical volatility and very poor performance | |
| The company reported the revenue of 510.6 M. Net Loss for the year was (347.87 M) with profit before overhead, payroll, taxes, and interest of 303.48 M. | |
| Genscript Biotech has accumulated about 1.26 B in cash with (136.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Roughly 38.0% of the company shares are held by company insiders |
- Analyzing Genscript Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genscript Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Genscript Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Genscript Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genscript Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Genscript Biotech's pink sheet. These opinions can provide insight into Genscript Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Genscript Pink Sheet analysis
When running Genscript Biotech's price analysis, check to measure Genscript Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genscript Biotech is operating at the current time. Most of Genscript Biotech's value examination focuses on studying past and present price action to predict the probability of Genscript Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genscript Biotech's price. Additionally, you may evaluate how the addition of Genscript Biotech to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |